The impact of genomic mutational status on PD-L1 expression and tumor mutation burden in non-small cell lung cancer

被引：1
|
作者：
Zhou, Qing [1 ,2 ]
Gu, Weiguang [3 ]
Fu, WenFan [4 ]
Mai, Shijie [5 ]
Lin, Daren [6 ]
Zhang, Shiyue [7 ]
Wang, Wenjing [7 ]
Zhang, Peng [7 ]
机构：
[1] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Peoples Hosp Nai Hai, Foshan City Chancheng Area, Foping St 40, Foshan, Peoples R China
[4] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Guangdong, Peoples R China
[5] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Jiangmen Hosp, Jiangmen Cent Hosp, Jiangmen, Peoples R China
[7] OrigiMed, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-1691
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1691
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clinicopathological and genomic correlates of PD-L1 expression in nonsquamous non-small cell lung cancer
    Lamberti, Giuseppe
    Spurr, Liam
    Li, Yvonne
    Ricciuti, Biagio
    Recondo, Gonzalo
    Umeton, Renato
    Cherniak, Andrew
    Meyerson, Matthew
    Awad, Mark
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [22] Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene
    Fischer, Alessa
    Bankel, Lorenz
    Hiltbrunner, Stefanie
    Rechsteiner, Markus
    Ruschoff, Jan H.
    Rushing, Elisabeth Jane
    Britschgi, Christian
    Curioni-Fontecedro, Alessandra
    [J]. TARGETED ONCOLOGY, 2022, 17 (06) : 683 - 694
  • [23] Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene
    Alessa Fischer
    Lorenz Bankel
    Stefanie Hiltbrunner
    Markus Rechsteiner
    Jan H. Rüschoff
    Elisabeth Jane Rushing
    Christian Britschgi
    Alessandra Curioni-Fontecedro
    [J]. Targeted Oncology, 2022, 17 : 683 - 694
  • [24] Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
    Shao, Min-min
    Xu, Yue-ping
    Zhang, Jin-jing
    Mao, Mao
    Wang, Meng-chuan
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1446 - 1458
  • [25] Quantification of PD-L1 expression in non-small cell lung cancer
    Verma, Vivek
    Chang, Joe Y.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S402 - S404
  • [26] PD-L1 Expression in Patients with Non-small Cell Lung Cancer
    Masago, Katsuhiro
    Fujita, Shiro
    Hata, Akito
    Okuda, Chiyuki
    Kaji, Reiko
    Katakami, Nobuyuki
    Hirata, Yukio
    [J]. ANTICANCER RESEARCH, 2017, 37 (05) : 2269 - 2274
  • [27] PD-L1 expression testing in non-small cell lung cancer
    Teixido, Cristina
    Vilarino, Noelia
    Reyes, Roxana
    Reguart, Noemi
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [28] PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations
    Ma, Tiantian
    Jiao, Jin
    Huo, Ran
    Li, Xiaofang
    Fang, Guotao
    Zhao, Qi
    Liu, Weiwei
    Han, Xiao
    Xi, Chenglin
    Wang, Yanan
    Shang, Yanhong
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
    Dong, Aoran
    Zhao, Yiming
    Li, Zhihua
    Hu, Hai
    [J]. JOURNAL OF GENE MEDICINE, 2021, 23 (02):
  • [30] Inter-tumor Heterogeneity of PD-L1 Expression in Non-small Cell Lung Cancer
    Saito, Y.
    Wakimoto, S.
    Morooka, H.
    Ibi, T.
    Yamauchi, Y.
    Takahashi, N.
    Shimizu, Y.
    Ikeya, T.
    Sakao, Y.
    Kawamura, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S568 - S569
12345